Oncology Central

How should we manage bevacizumab toxicity in lung cancer patients?

0

Bevacizumab is an antiangiogenic targeted therapy approved for the treatment of patients with advanced non-small-cell lung cancer other than predominantly squamous cell histology in addition to platinum-based chemotherapy. The safety of bevacizumab has been assessed in studies across most cancer types and bevacizumab is generally well tolerated.

To view restricted content, please:
Share:

Leave A Comment